Phase 3 Readout~month

Phase 3 Topline: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clin

Name: Phase 3 Topline: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clin
Start: 2031-10-01

October 1, 2031

Company: Immatics N.V. (IMTX)
Drug: previously
Indication: Melanoma, Cutaneous Malignant

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clin — IMTX Phase 3 Readout | BioSniper